Article

CURE's Top 5 Stories: February 2019

Author(s):

Jessica Skarzynski

Here are the top 5 CURE stories for February 2019.

Here are the top 5 CURE stories for February 2019.

5. Young and (Cancer) Free

Although they no longer face the disease, adolescent and young adult cancer survivors live with hardships — which we take a closer look at in this piece.

4. Imbruvica in Elderly Patients with CLL

We break down the results of a recent trial presented in the New England Journal of Medicine, that found that Imbruvica may be superior to standard of care in some elderly patients with chronic lymphocytic leukemia.

3. Sweet Surrender

In this story, take a closer look at how experts have determined that banishing sugar and extra body fat can be important tools in preventing cancer.

2. Fatigue, Chemo Brain and Other Symptoms

Here, one expert discusses how cancer and its treatments can have many lasting side effects on patients, from depression to peripheral neuropathy.

1. Will I Reach My Goal?

CURE Contributor Jane Biehl shares her thoughts on life as a cancer survivor and enjoying every step it takes to reach her goals.

Did you know that CURE has a podcast? And that it’s celebrating its first birthday this month? CURE Talks Cancer is a weekly podcast about what CURE does best: provide cancer updates, research and education. Visit curetoday.com/podcasts and catch up on a year’s worth of discussions with patients, caregivers, doctors and advocates — and subscribe today so you don’t miss another episode!

And as always, for links to all of our top stories and more, visit curetoday.com.

Related Videos
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Image of doctor with black hair.
Image of woman with blonde hair.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
a man and a woman in front of a dark blue background
Image of woman with black hair.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Related Content
Childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population: © Konstantin Yuganov - stock.adobe.com
March 28th 2025

Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

Alex Biese
Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read Chester's blogs here!
March 25th 2025

Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia

Chester Freeman
Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce - stock.adobe.com.
March 18th 2025

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

Spencer Feldman
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
Digital illustration of human figure with glowing neural pathways, highlighting neuropathic pain in spine and limbs, emphasizing complexity of nervous system | Image Credit: © KM - AI generated.
March 18th 2025

First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain

Ryan Scott
The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.